+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 15 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are conducting a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of three different dose regimens of MORF-057 in adults with moderately to severely active Crohns disease CD. The study aims to assess how well MORF-057 works compared to placebo during induction therapy in this patient population. The trial is conducted across multiple centers and includes adults aged 18 to 85 years with active CD as defined by clinical and endoscopic criteria. Participants will be randomly assigned to one of three blinded groups receiving different doses of MORF-057 or matching placebo during a 14-week Induction Period. Following this, all participants will receive open-label MORF-057 during a 38-week Maintenance Period. Those who complete the full 52-week treatment phase may continue treatment in a 52-week Long-Term Extension to further assess long-term effects. Throughout the study, participants will undergo assessments including the Simple Endoscopic Score for Crohns Disease SES-CD at week 14 to measure endoscopic response, and the Crohns Disease Activity Index CDAI to evaluate clinical response and remission. Safety and tolerability will be monitored regularly. The total study duration for participants can extend up to 104 weeks including the extension phase, with frequent visits and evaluations to monitor disease activity and treatment effects.

Age: 18Years - 85YearsAll GendersPhase 2
224 locations
E

Actively Recruiting

Researchers are evaluating whether tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after the person was last seen well. This study focuses on people who had a stroke caused by a clot blocking a brain blood vessel and have imaging showing brain tissue that can still be saved. Participants are excluded if they are planned for a procedure to remove the clot. Participants are randomly placed into two groups. One group receives a single intravenous injection of tenecteplase, while the other group receives standard medical care. The trial compares these treatments to see if tenecteplase improves recovery when given later than the usual 4.5-hour window after stroke onset. Participants stay in the study for about three months, including roughly one week in the hospital. They undergo seven clinical visits or exams, with the last two likely done remotely from home. Doctors assess recovery using a scale that measures disability and dependence in daily life. They also monitor health and any side effects to compare outcomes between the two groups.

Age: 18Years +All GendersPhase 3
257 locations
O

Actively Recruiting

Researchers are studying adults in Kazakhstan who have metabolic dysfunction-associated steatotic liver disease MASLD to better understand how this liver condition appears and is managed in everyday medical care. The study includes about 420 adults with MASLD, focusing on their health characteristics and how the disease affects them. A smaller group of about 65 participants in Almaty, who were already prescribed Ursosan by their doctors, will be followed to observe changes in liver-related health measures. The study has two parts a cross-sectional component where information from medical records, lab tests, liver imaging, and questionnaires is collected once for each participant and a prospective cohort component that follows the subgroup receiving Ursosan for approximately six months. During this follow-up, participants will have remote contacts at about 2 and 4 months and a final assessment at 6 months. Treatment decisions, including the use of Ursosan, are made by the participants doctors as part of routine care, not assigned by the study. Participants will provide data through routine medical care records, imaging scans, laboratory tests, and questionnaires about lifestyle and health. Researchers will measure liver health through imaging, liver enzyme levels, and fibrosis assessments. The study monitors changes in these measures over time, especially in the Ursosan subgroup. Participation may last up to six months for some, while others contribute data at a single time point, helping researchers understand MASLD and responses to Ursosan in real-world settings.

Age: 18Years - 65YearsAll Genders
7 locations
F

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the CorWave Left Ventricular Assist System LVAS for treating patients with advanced heart failure. This prospective, multi-center, non-randomized trial focuses on adults aged 18 to 75 years who have advanced left ventricular heart failure and meet specific heart function criteria. The study is sponsored by CorWave and aims to assess survival and freedom from adverse events related to the device. Participants will receive implantation of the CorWave LVAS device to support heart function. The study follows a single group design where all participants receive this advanced device to treat their condition. The treatment period includes monitoring for survival and device-related complications, with outcome measurements extending up to two years after implantation. During the study, participants undergo regular assessments including evaluations of survival 30 days post-implant, adverse events, quality of life, neurocognitive function, and functional status up to two years. Researchers will also track freedom from bleeding, infection, stroke, and other complications at various time points. The total participation duration spans up to two years with ongoing safety and health monitoring throughout the study.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
3 locations
C

Actively Recruiting

Researchers are investigating different ways to reduce weight in adults aged 35 to 65 years who have metabolic syndrome, including type 2 diabetes and hypertension. This study aims to compare the effects of drug treatment, surgery, and diet on lifespan, blood sugar control, blood fat levels, quality of life, and cost-effectiveness over 24 weeks. The study includes patients with obesity and metabolic syndrome complications, examining how these approaches influence health outcomes. The study has four groups one receives a combination of medications including Semaglutide and Empagliflozin alongside standard treatments another undergoes a surgical procedure called minigastric bypass to reduce food absorption a third follows a very-low-calorie diet with fat-free vegetables and controlled salt intake combined with physical activity and the fourth group practices fasting during the Ramadan period following specific dietary rules. Treatments and lifestyle changes are monitored over 24 weeks with ongoing support through in-person and phone consultations. Participants will have regular assessments including weight, blood sugar, insulin levels, blood pressure, cholesterol, and bone density measured at the start and end of the study. Other evaluations include body composition analysis, ultrasound, electrocardiograms, and quality of life questionnaires. The study also measures telomere length as a marker of cellular health. Safety, treatment adherence, and cost-effectiveness are tracked throughout, with all participants continuing their standard care during the trial.

Age: 35Years - 65YearsAll GendersPhase 4
1 location
O

Actively Recruiting

Researchers are studying approximately 240 adult patients in Kazakhstan who have HER2-positive metastatic breast cancer mBC and are receiving anti-HER2 therapy, excluding trastuzumab deruxtecan. This observational retrospective study aims to evaluate real-world treatment approaches, clinical outcomes, and patient characteristics across 12 oncology centers to provide a representative sample of this population. The study covers patients diagnosed with mBC between January 2022 and December 2023 and includes a follow-up period to assess treatment impact. The study collects data retrospectively from patient medical records starting from the date of mBC diagnosis until either the patients death or the end of the study, which is at least 12 months after the latest diagnosis date. The treatments under review include all anti-HER2 therapies except trastuzumab deruxtecan. Researchers will analyze treatments received, diagnostic methods, therapy discontinuation reasons, lines of anticancer therapy, and efficacy in routine clinical practice. Participants data will be reviewed for at least 24 months following diagnosis, unless the patient died, moved, or refused therapy within that period. The primary outcome is to assess median progression-free survival and its rate over up to two years. Secondary outcomes include describing patient demographics, diagnostic and therapeutic patterns, treatment approaches, efficacy, reasons for stopping therapy, and number of therapy lines. This design involves no direct intervention, and data collection is based on existing medical records.

Age: 18Years - 99YearsAll Genders
12 locations
I

Actively Recruiting

Researchers are evaluating the real-world effects of adding anifrolumab to standard treatment for patients with Systemic Lupus Erythematosus SLE. This multi-country observational study aims to gather important information on how anifrolumab works in routine clinical practice across various countries, including those in the Gulf Cooperation Council, Latin America, Taiwan, and Egypt. The study uses standardized criteria and assessments to compare results across these locations. Participants who have been prescribed anifrolumab for the first time will be followed prospectively for one year after their initial infusion. The study also collects data from the year before starting anifrolumab to understand baseline health status. Clinical assessments relevant to SLE, including specific measures for skin symptoms, are used to monitor the patients. The study continues to collect data even if patients stop anifrolumab treatment, unless they withdraw consent. During the study, participants will undergo clinical and patient-reported evaluations at baseline and multiple points over one year, including assessments like PGA, SLEDAI-2K, CLASI, FACIT-Fatigue, LupusQoL, and EQ-5D-5L. Researchers will monitor these outcomes to understand how patients respond to anifrolumab in everyday care. The study period continues until the end of 2027 or until patients discontinue participation, with careful follow-up to capture ongoing health information.

Age: 18Years +All Genders
32 locations
P

Actively Recruiting

Researchers are evaluating the clinical effectiveness of PD-1 inhibitors as maintenance therapy after autologous hematopoietic stem cell transplantation auto-HSCT in patients with relapsed or refractory classical Hodgkin lymphoma cHL. This phase II study focuses on preventing relapse and disease progression in patients who often experience these within two years after auto-HSCT. Current treatments like brentuximab vedotin have improved outcomes but still show limitations, making PD-1 inhibitors a promising alternative due to their favorable toxicity profile and potential for durable remission. Participants will receive maintenance therapy using PD-1 inhibitors, either nivolumab or pembrolizumab, as decided by the study center. Nivolumab is given intravenously either as a fixed 40 mg dose every two weeks for up to 12 cycles or at 3 mgkg every two weeks for up to 12 cycles. Pembrolizumab is administered as a fixed 200 mg dose intravenously every three weeks for up to 8 cycles. Treatment should begin within 60 days after transplantation, with some exceptions allowed under study leadership guidance. Throughout the study, participants will be closely monitored with assessments including imaging scans, blood tests, and evaluation of adverse events. The main outcome measured is progression-free survival at 24 months after starting maintenance therapy, alongside secondary measures such as survival rates and relapse incidence at 12, 18, and 24 months. Safety and tolerability will also be tracked during therapy and for one year after treatment completion. The overall study duration extends to September 2030.

Age: 18Years - 70YearsAll GendersPhase 2
4 locations
P

Actively Recruiting

Acute respiratory distress syndrome ARDS is a serious lung condition causing inflammation and fluid buildup, leading to severe breathing problems and high mortality in intensive care units worldwide. Despite many clinical trials, no specific drug has yet proven effective in treating ARDS. The study aims to evaluate the anti-fibrotic medication Pirfenidone, previously used for idiopathic pulmonary fibrosis, to see if it can prevent lung fibrosis and improve outcomes in ARDS patients. Participants will be randomly assigned to receive either Pirfenidone or a placebo. Pirfenidone dosing starts at 801 mg per day for the first week, increases to 1602 mg per day for the second week, and then to 2403 mg per day until ICU discharge. The medication or placebo is given through a nasogastric tube in three divided doses daily. This is a phase 3 randomized controlled trial conducted across multiple centers. Throughout the study, researchers will monitor the number of days participants are free from ventilators within 28 days, length of ICU stay, lung imaging changes, mortality rates, lung function tests, heart function, and quality of life up to one year. Samples from the lungs will also be collected to study inflammation. Safety and any adverse effects will be closely tracked. The study will continue until December 2026.

Age: 18Years +All GendersPhase 3
17 locations
P

Actively Recruiting

Gastric cancer is a common and serious disease, ranking as the fifth most frequent cancer worldwide and the third leading cause of cancer-related deaths. Patients with locally advanced gastric cancer often face the challenge of peritoneal carcinomatosis PC, a condition occurring in 60% of cases after surgery and linked to poor outcomes. Researchers are evaluating whether adding a new preoperative treatment called pressurized intraperitoneal aerosolized chemotherapy PIPAC can reduce the occurrence of PC compared to standard treatment alone. The study compares two groups one receiving PIPAC with the chemotherapy drugs cisplatin and doxorubicin before standard perioperative chemotherapy FLOT regimen and surgery including gastrectomy with lymphadenectomy the other group is a retrospective cohort receiving only the standard chemotherapy and surgery. PIPAC delivers chemotherapy as an aerosol directly to the peritoneal surface, aiming to penetrate tumor implants more deeply while minimizing side effects. Participants will be monitored through scheduled assessments, including evaluations of survival rates, disease progression, quality of life using the EORTC QLQ-C30 questionnaire, and safety events. The main outcome is the incidence of peritoneal carcinomatosis at 12 and 24 months after surgery. Secondary outcomes include overall and disease-free survival, adverse events, and pathological response. The study begins in January 2025 and will follow participants over multiple years to gather these results.

Age: 18Years +All GendersPhase Not Applicable
1 location

1-10 of 15

1